The right prevention and treatment for the right patient at the right time

Esther Schenker, PhD

Institut de Recherches Servier

Croissy

Key figures

- Founded in 1954 by Dr. J. Servier

- Presence in 140 countries worldwide

- More than 89 % of drug sales made internationally

- More than 20,000 employees worldwide with nearly 3,000 in R&D

Therapeutic areas of interest

- Cardiovascular: hypertension, ischemic heart disease, heart failure, chronic venous disease

- Oncology

- Rheumatology: osteoporosis, osteo-arthritis

- Metabolic diseases: type II diabetes

- Neurosciences: neurodegenerative diseases, psychiatric disorders

SERVIER
Life through Discovery

efpia

# SERVIER in Hungary

A 20-year presence

EGIS SA
- 3000 empolyees
- Domestic market share 7.1%

Servier Research Institute of Medicinal Chemistry (SRIMC)

Local Center of Clinical Research (ICTR)

Life through Discovery

Fruitful exchanges through partnership

Pre-competitive collaborations

Drug safety:

Knowledge Management:

Metabolism:

Oncology:

Neuroscience:

Newly started projects: APPROACH, PEX-BRB, PRECISEAD, SPRINT-T

Burden ≠ Investment

Adapted from Catalá-López et al., 2010

Key challenges

Challenge

Why do patients not respond well to current medication?

Question:

Can we identify groups of patients and medications that match better?

> **Clinical phenotype**
> **Biological phenotype**
> **Animal models**
> **Clinical trials in a meaningful way**
>> ☛ **A clear need for better tools**

SERVIER
Life through Discovery

efpia

The need for PrivatePublicPartnerships

- **The scientific questions that remain unanswered e.g. in psychiatry are extremely complex**
  - **-** One organisation cannot solve the problem alone

- **Need of platforms to join forces**
  - **-** IMI has successfully provided such platforms

SERVIER
Life through Discovery

efpia

Why platforms

☛ **Improve access to clinical data**

Research data are scattered among many small cohort studies

Electronic health registry data are not easily accessible

health insurance data
Hospital data
General practitioner registries
Pharmacy registries

SERVIER
Life through Discovery

efpia

Highlights - Opportunities

Examples from newmeds

Psychiatry database with data from 23 401 patients enrolled in 59 studies (data from Big Pharma)

- ☛ 4 week studies are sufficient

Antidepressant database with data from 12 217 patients enrolled in 39 trials (data from Big Pharma)

- ☛ females show less placebo response
- ☛ more males are included in trials

SERVIER
Life through Discovery

efpia

Highlights - Opportunities

Sadly,

Not yet changed the lives of patients suffering from Schizophrenia or depression

But we have:
- Gained insight into the biology of the disease
- Developed novel tools for drug discovery [animal models, human imaging]
- Developed a new web tool for analyses [image analysis, biomarker significance]

SERVIER

*Life through Discovery*

efpia

Collaboration between SME, Academia and Industry

CNVs conferring risk of autism or schizophrenia affect cognition in controls

Hreinn Stefansson[1]*, Andreas Meyer–Lindenberg[2]*, Stacy Steinberg[1], Brynja Magnusdottir[3], Katrin Morgen[2], Sunna Arnarsdottir[1,3], Gyda Bjornsdottir[1], G. Bragi Walters[1], Gudrun A. Jonsdottir[1], Orla M. Doyle[4], Heike Tost[2], Oliver Grimm[2], Solveig Kristjansdottir[1], Heimir Snorrason[1], Solveig R. Davidsdottir[3], Larus J. Gudmundsson[1], Gudbjorn F. Jonsson[1], Berglind Stefansdottir[1], Isafold Helgadottir[3], Magnus Haraldsson[3,5], Birna Jonsdottir[6], Johan H. Thygesen[7], Adam J. Schwarz[8], Michael Didriksen[9], Tine B. Stensbøl[9], Michael Brammer[4], Shitij Kapur[4], Jonas G. Halldorsson[5], Stefan Hreidarsson[10], Evald Saemundsen[5,10], Engilbert Sigurdsson[3,5] & Kari Stefansson[1]

- Cognitive abilities of CNV carriers are in between normal controls and schizophrenic patients
- Cognitive abnormalities are not necessarily consequences of the disease

Highlights - Opportunities

Characterization of 3 CNV high risk genes in humans and rodents

22q11
15q13
1q21

15q13.3
Schizophrenia
Developmental delay

Seizures

Schizophrenia
Di George
syndrome
Anxiety
Depression
ADHD
OCD
22q11.2

Schizophrenia
Generalized epilepsy
Mental retardation

1q21.1

Full translational approach

SHANK3

iPS cells

mice

rats

EU-AIMS

SERVIER
Life through Discovery

efpia

Highlights - Opportunities

Examples from EU-AIMS

Autism Research in Europe

Clinical network

⚕ Building a large network of expert Autism Spectrum disorder (ASD) clinical research centers across Europe

⚕ 78 sites in 37 countries

⚕ Harmonization of diagnostic practice

⚕ Creation of an interactive platform for ASD professionals and patients

SERVIER
Life through Discovery

efpia

Highlights - Opportunities

EU-AIMS
Autism Research in Europe

- ✠ Development and validation of translational approaches for the advancement of novel therapies to treat ASD

- ✠ Setting new standards in research and clinical development to aid the drug discovery process

SERVIER
Life through Discovery

efpia

The network ...

... creates opportunities, ..

... grey matter, innovation!

SERVIER
Life through Discovery

efpia